{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Subsequent to TLI/ATG/TBI conditioning, the proportion of participants with full dose donor chimerism (FDC) will be determined by Day 28. FDC is defined as achieving ≥ 95% donor type in the CD3+ lineage within 28 days of donor cell infusion, as assessed by short tandem repeat (STR) testing. The outcome will be expressed as the number of participants that achieve FDC by Day 28, a number without dispersion.","groups":[{"description":"TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)\n\nTotal body irradiation (TBI): Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning\n\nAnti-thymocyte globulin (ATG): Given intravenous (IV), Dose 1.5 mg/kg x 5 days\n\nTacrolimus: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)\n\nMycophenolate mofetil (MMF): Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.\n\nTotal lymphoid irradiation (TLI): 9 x 120 cGy over 11 days","id":"OG000","title":"TBI+TLI"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 28","title":"Full-dose Donor Chimerism (FDC) at Day 28 Following TLI/ATG/TBI Conditioning.","type":"PRIMARY","unitOfMeasure":"Participants"}